Hematology News

The diligence and awareness to stay home demonstrated by patients with sickle cell disease during the COVID-19 pandemic proved crucial in reducing morbidity and mortality, according to a study presented at ASH Annual Meeting and Exposition.

Clonal hematopoiesis of indeterminate potential, which has been shown to substantially increase risk for blood cancer and cardiovascular disease, also appeared associated with protection from Alzheimer’s disease, according to study results.

A novel high-sensitivity screening approach led to detection of monoclonal gammopathy of undetermined significance at significantly higher rates than conventional methods among people at high risk for multiple myeloma, study results showed.

The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.

The FDA granted priority review to luspatercept-aamt for treatment of anemia among adults with non-transfusion-dependent beta-thalassemia.

The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, according to results of a nonrandomized phase 1/phase 2 dose-escalation study published in The New England Journal of Medicine.

In patients who underwent knee arthroplasty, milvexian, a novel factor XIa inhibitor, was effective at preventing venous thromboembolism and was linked to a low rate of bleeding, researchers reported.

An IV monoclonal antibody accomplished quick and sustained reversal of the antiplatelet effects of ticagrelor, according to the REVERSE-IT trial presented at the American Heart Association Scientific Sessions.

Staying ahead of inflammation and managing the broad range of symptoms is key to controlling VEXAS syndrome, according to data presented at ACR Convergence 2021.

In patients hospitalized with COPD exacerbations, those who received usual care plus an active strategy for diagnosing pulmonary embolism did not have improved outcomes compared with those who received usual care only.